| [1] |
Wolff A P, Maltzke M A. Epigenetics: regulation through repression. Science,1999,286:481 -486.
|
| [2] |
Frühwald M C, Plass C. Global and gene-specific methylation patterns in cancer: aspects of tumor biology and clinical potential. Mol Genet Metab,2002,75:1 -16.
|
| [3] |
Paola P,Maria L P,Antonietta P G,et al. Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors.Clin Cancer Res,2004,10:5349-5354.
|
| [4] |
Jyoti M,Mustafa V,Megan M V,et al. Very high frequency of hypermethylated genes in breast cancer metastasis to the bone,brain,and lung. Clin Cancer Res,2004,10:3104 -3109.
|
| [5] |
Look M P, van Putten W L, Duffy M J, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst,2002,94:116 -128.
|
| [6] |
Pouya P, Bernard T, Shafaat A R. Demethylation of urokinase promoter as a prognostic marker in patients with breast carcinoma. Clin Cancer Res,2004,10:3035 -3041.
|
| [7] |
Ji H, Liu Y, Jia T. Identification of a breast cancer-specific gene. BCSG1,by direct differential cDNA sequencing. Cancer Res,1997,57:759 -764.
|
| [8] |
Anu G,Andrew K G,Lisa V. Hypomethylation of the synuclein γ gene CpG Island promotes its aberrant expression in breast carcinoma and ovarian carcinoma. Cancer Res,2003,63:664 -673.
|
| [9] |
Guillermo B, Andrea S, Joachim M, et al. Gadd45a promotes epigenetic gene activation by repair-mediated DNA demethylation.Nature,2007,445:671-675.
|
| [10] |
Fatima B,Christopher B,Ranjaka G,et al. SWI/SNF chromatinremodeling factors induce changes in DNA methylation to promote transcriptional activation. Cancer Res, 2005, 65:3542 -3547.
|
| [11] |
David S M, Li J W, Jiemin W. Relationship between histone H3 lysine 9 methylation,transcription repression,and heterochromatin protein 1 recruitment. Mol Cell Biol,2005,25:2525 -2538.
|
| [12] |
Gayther S A, Battey S J, Linger L, et al. Mutations truncating the EP300 aceltylase in human cancer. Nat Genet,2000,24:300 -303.
|
| [13] |
Kawai H, Li H, Avraham S, et al. Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha. Int J Cancer,2003,107:353 -358.
|
| [14] |
Zhang Z, Yamashita H, Toyama T, et al. HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res,2004,10:6962 -6968.
|
| [15] |
William J M, Rajeev S S, James E H, et al. Breast cancer metastasis suppressor 1 ( BRMS1) forms complexes with retinoblastoma-binding protein 1 (RBP1) and the mSin3 histone deacetylase complex and represses transcription. J Biol Chem,2004,279:1562 -1569.
|
| [16] |
Robert J K, Kenichi Y, Yangjin B, et al. The transcriptional repressor JHDM3A demethylates trimethyl histone H3 lysine 9 and lysine 36. Nature,2006,442:312 -316.
|
| [17] |
Kenichi Y, Keisuke T, Robert J K, et al. PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. Mol Cell,2007,25:801 -812.
|
| [18] |
Sandip K M, Mahitosh M, Abhijit M, et al. Dynamic chromatin remodeling on the HER-2 promoter in human breast cancer cells. FEBS Letters,2001,507:88 -94.
|
| [19] |
Inge S P, Peter A D, Dennise B, et al. Frequent loss of imprinting of PEG1/MEST in invasive breast cancer. Cancer Res,1999,59:5449 -5451.
|
| [20] |
Luo R Z, Fang X, Marquez R, et al. ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers. Oncogene,2003,22:2897 -2909.
|
| [21] |
Bao J J,Le X F, Wang R Y, et al. Re-expression of the tumor suppressor gene ARHI induces apoptosis in ovarian and breast cancer cells through a caspase-independent calpain-dependent pathway. Cancer Res,2002,62:7264 -7272.
|
| [22] |
Jiuhong Y, Robert Z L, Satoshi F, et al. Aberrant methylation and silencing of ARHI,an imprinted tumor suppressor gene in which the function is lost in breast cancers. Cancer Res,2003,63:4174 -4180.
|
| [23] |
Roozendaal C E P, Gillis A J M, Klijn J G M, et al. Loss of imprinting of IGF2 and not H19 in breast cancer,adjacent normal tissue and derived fibroblast cultures. FEBS Letters,1998,437:107 -111.
|
| [24] |
Calin G A, Sevignani C, Dumitru C D, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA,2004,101:2999 -3004.
|
| [25] |
Marilena V I, Manuela F, Chang Gong L, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res,2005,65:7065 -7070.
|
| [26] |
Jang E R, Lim S J, Lee E S, et al. The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alphanegative breast cancer cells to tamoxifen. Oncogene,2004,23:1724 -1736.
|
| [27] |
Zhu W G, Lakshmanan R R, Beal M D, et al. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res,2001,61:1327-1333.
|
| [28] |
Yeung F, Law W K, Yeh C H, et al. Regulation of human osteocalcin promoter in hormone-independent human prostate cancer cells. J Biol Chem,2002,77:2468 -2476.
|
| [29] |
Pratap J,Javed A,Languino L R,et al. The Runx2 osteogenic transcription factor regulates Matrix Metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol,2005,25:8581 -8591.
|
| [30] |
Pan Q,Bao L W,Kleer C G,et al. Protein kinase C epsilon is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapy.Cancer Res,2005,65:8366 -8371.
|